Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
70 hedge funds and large institutions have $291M invested in Sio Gene Therapies Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 13 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
30% more call options, than puts
Call options by funds: $392K | Put options by funds: $301K
0% more funds holding
Funds holding: 70 → 70 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
36% less capital invested
Capital invested by funds: $454M → $291M (-$163M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$16.7M |
| 2 |
VMI
VHCP Management II
New York
|
+$5.73M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.64M |
| 4 |
VM
VHCP Management
New York
|
+$2.45M |
| 5 |
Asset Management One
Tokyo,
Japan
|
+$991K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$11.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$5.54M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.11M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$3.91M |
| 5 |
ACM
Atika Capital Management
New York
|
-$1.89M |
SIOX Hedge Fund Activity: Q1 2016 in Review
70 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2016, worth a combined $291M — down 36% from $454M a quarter earlier.
Fund positioning in SIOX was balanced in Q1 2016: 13 funds opened new positions, 13 closed out, 25 added to existing stakes and 19 trimmed.
The largest buyer was Janus Henderson Investors US, adding an estimated $16.7M. The largest seller was Visium Asset Management, cutting an estimated $11.8M.
- 70 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $291M of Sio Gene Therapies Inc. Common Stock stock for Q1 2016, down 36% quarter-over-quarter.
- 13 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2016 and 13 closed out, a net change of 0 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2016 was Janus Henderson Investors US, an estimated $16.7M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2016 was Visium Asset Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q1 2016.